Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Illumina Inc. (NASDAQ:ILMN)

Common Stock Valuation Ratios (Price Multiples)

Beginner level

Current Valuation Ratios

Illumina Inc., current price multiples

Microsoft Excel LibreOffice Calc
Illumina Inc. AbbVie Inc. Amgen Inc. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Zoetis Inc. Pharmaceuticals, Biotechnology & Life Sciences Health Care
Selected Financial Data
Current share price (P) $461.05
No. shares of common stock outstanding 146,000,000
Growth rate (g) 20.99%
 
Earnings per share (EPS) $4.49
Next year expected EPS $5.44
Operating profit per share $3.97
Sales per share $22.18
Book value per share (BVPS) $32.15
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 102.61 43.90 19.00 34.48 686.74 29.32 27.50 22.95 16.20 29.81 54.09 30.56 37.69
Price to next year expected earnings 84.81 44.99 14.62 26.86 35.66 28.40 21.63 13.00 26.91 38.00 28.05 35.09
Price-earnings-growth (PEG) 4.89 0.63 1.22 3.78 0.66 2.76 1.28 3.42 5.09
Price to operating profit (P/OP) 116.06 17.83 15.10 35.25 20.75 22.14 24.58 27.04 15.92 24.38 39.48 23.49 27.28
Price to sales (P/S) 20.78 4.42 5.69 8.70 3.47 5.22 4.05 5.27 6.70 5.90 13.27 5.52 3.33
Price to book value (P/BV) 14.34 15.50 14.67 37.85 4.64 6.82 7.68 3.49 5.16 5.51 23.51 7.49 5.66

Based on: 10-K (filing date: 2021-02-17).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

Illumina Inc., historical price multiples

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Price to earnings (P/E) 109.92 43.43 52.00 44.63 52.01
Price to operating profit (P/OP) 124.33 44.17 48.64 53.47 40.99
Price to sales (P/S) 22.26 12.28 12.89 11.77 10.03
Price to book value (P/BV) 15.36 9.43 11.43 11.79 10.95

Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Illumina Inc.’s P/E ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Illumina Inc.’s P/OP ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Illumina Inc.’s P/S ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Illumina Inc.’s P/BV ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.

Price to Earnings (P/E)

Illumina Inc., historical P/E calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
No. shares of common stock outstanding1 145,900,000 147,000,000 147,000,000 147,000,000 146,300,000
Selected Financial Data (US$)
Net income attributable to Illumina stockholders (in millions) 656  1,002  826  726  463 
Earnings per share (EPS)2 4.50 6.82 5.62 4.94 3.16
Share price1, 3 494.24 296.00 292.20 220.44 164.46
Valuation Ratio
P/E ratio4 109.92 43.43 52.00 44.63 52.01
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 40.17 17.82 20.60 35.47 16.54
Amgen Inc. 18.82 17.07 14.01 64.06 16.03
Eli Lilly & Co. 31.95 16.19 39.13 32.39
Gilead Sciences Inc. 641.48 16.45 15.26 22.75 6.83
Johnson & Johnson 28.92 25.99 23.74 268.10 20.08
Merck & Co. Inc. 26.72 20.60 33.46 61.63 46.14
Pfizer Inc. 19.62 11.63 21.58 9.99 28.10
Regeneron Pharmaceuticals Inc. 15.09 19.86 18.17 28.99 42.64
Thermo Fisher Scientific Inc. 27.89 33.36 35.19 37.66 30.45
Zoetis Inc. 48.25 45.89 28.68 44.09 31.63
P/E Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 28.88 19.75 23.59 33.63 20.53
P/E Ratio, Industry
Health Care 34.55 22.54 26.52 32.85 22.21

Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).

1 Data adjusted for splits and stock dividends.

2 2020 Calculation
EPS = Net income attributable to Illumina stockholders ÷ No. shares of common stock outstanding
= 656,000,000 ÷ 145,900,000 = 4.50

3 Closing price as at the filing date of Illumina Inc.’s Annual Report.

4 2020 Calculation
P/E ratio = Share price ÷ EPS
= 494.24 ÷ 4.50 = 109.92

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Illumina Inc.’s P/E ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.

Price to Operating Profit (P/OP)

Illumina Inc., historical P/OP calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
No. shares of common stock outstanding1 145,900,000 147,000,000 147,000,000 147,000,000 146,300,000
Selected Financial Data (US$)
Income from operations (in millions) 580  985  883  606  587 
Operating profit per share2 3.98 6.70 6.01 4.12 4.01
Share price1, 3 494.24 296.00 292.20 220.44 164.46
Valuation Ratio
P/OP ratio4 124.33 44.17 48.64 53.47 40.99
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 16.32 10.82 18.35 19.63 10.49
Amgen Inc. 14.96 13.84 11.46 12.71 12.64
Eli Lilly & Co. 32.66 27.08 33.99 39.61 25.63
Gilead Sciences Inc. 19.38 20.66 10.15 7.45 5.23
Johnson & Johnson 21.84 19.83 18.34 18.94 16.09
Merck & Co. Inc. 23.89 17.47 25.08 22.58 33.62
Pfizer Inc. 23.12 14.36 17.19 15.62 16.88
Regeneron Pharmaceuticals Inc. 14.82 19.01 17.53 16.71 28.70
Thermo Fisher Scientific Inc. 22.81 26.84 27.33 28.24 25.13
Zoetis Inc. 35.22 35.00 22.59 22.33 18.65
P/OP Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 22.19 18.09 18.68 17.16 15.09
P/OP Ratio, Industry
Health Care 25.01 19.16 19.73 18.13 15.56

Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).

1 Data adjusted for splits and stock dividends.

2 2020 Calculation
Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= 580,000,000 ÷ 145,900,000 = 3.98

3 Closing price as at the filing date of Illumina Inc.’s Annual Report.

4 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 494.24 ÷ 3.98 = 124.33

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Illumina Inc.’s P/OP ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.

Price to Sales (P/S)

Illumina Inc., historical P/S calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
No. shares of common stock outstanding1 145,900,000 147,000,000 147,000,000 147,000,000 146,300,000
Selected Financial Data (US$)
Revenue (in millions) 3,239  3,543  3,333  2,752  2,398 
Sales per share2 22.20 24.10 22.67 18.72 16.39
Share price1, 3 494.24 296.00 292.20 220.44 164.46
Valuation Ratio
P/S ratio4 22.26 12.28 12.89 11.77 10.03
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 4.05 4.22 3.58 6.67 3.84
Amgen Inc. 5.64 6.03 5.22 5.82 5.65
Eli Lilly & Co. 8.06 6.03 5.15 3.71 4.18
Gilead Sciences Inc. 3.24 4.00 3.84 4.10 3.08
Johnson & Johnson 5.15 4.79 4.45 4.56 4.62
Merck & Co. Inc. 3.93 4.33 4.92 3.68 4.54
Pfizer Inc. 4.50 3.66 4.49 4.05 3.84
Regeneron Pharmaceuticals Inc. 6.24 5.34 6.62 5.92 7.86
Thermo Fisher Scientific Inc. 5.52 4.83 4.24 4.01 3.37
Zoetis Inc. 11.84 11.00 7.03 7.18 5.31
P/S Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 5.21 4.82 4.66 4.64 4.32
P/S Ratio, Industry
Health Care 3.05 2.87 2.83 2.80 2.58

Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).

1 Data adjusted for splits and stock dividends.

2 2020 Calculation
Sales per share = Revenue ÷ No. shares of common stock outstanding
= 3,239,000,000 ÷ 145,900,000 = 22.20

3 Closing price as at the filing date of Illumina Inc.’s Annual Report.

4 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= 494.24 ÷ 22.20 = 22.26

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Illumina Inc.’s P/S ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.

Price to Book Value (P/BV)

Illumina Inc., historical P/BV calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
No. shares of common stock outstanding1 145,900,000 147,000,000 147,000,000 147,000,000 146,300,000
Selected Financial Data (US$)
Total Illumina stockholders’ equity (in millions) 4,694  4,613  3,758  2,749  2,197 
Book value per share (BVPS)2 32.17 31.38 25.56 18.70 15.02
Share price1, 3 494.24 296.00 292.20 220.44 164.46
Valuation Ratio
P/BV ratio4 15.36 9.43 11.43 11.79 10.95
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 14.18 36.95 21.24
Amgen Inc. 14.53 13.84 9.41 5.02 4.14
Eli Lilly & Co. 35.07 51.67 12.87 7.33 6.33
Gilead Sciences Inc. 4.33 3.93 3.89 5.15 4.88
Johnson & Johnson 6.72 6.61 6.08 5.79 4.72
Merck & Co. Inc. 7.46 7.83 7.79 4.30 4.51
Pfizer Inc. 2.98 3.00 3.80 2.98 3.40
Regeneron Pharmaceuticals Inc. 4.81 3.79 5.07 5.66 8.58
Thermo Fisher Scientific Inc. 5.15 4.16 3.75 3.30 2.86
Zoetis Inc. 20.97 25.42 18.74 21.52 17.46
P/BV Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 7.07 6.99 6.54 5.31 4.75
P/BV Ratio, Industry
Health Care 5.19 4.94 4.91 4.56 4.13

Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).

1 Data adjusted for splits and stock dividends.

2 2020 Calculation
BVPS = Total Illumina stockholders’ equity ÷ No. shares of common stock outstanding
= 4,694,000,000 ÷ 145,900,000 = 32.17

3 Closing price as at the filing date of Illumina Inc.’s Annual Report.

4 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= 494.24 ÷ 32.17 = 15.36

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Illumina Inc.’s P/BV ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.